Department of Endocrinology, Affiliated Hospital of Jining Medical University, Jining Medical University, Jining, China.
Chinese Research Center for Behavior Medicine in Growth and Development, Jining, China.
PLoS One. 2022 Jul 7;17(7):e0270899. doi: 10.1371/journal.pone.0270899. eCollection 2022.
Glucagon‑like peptide 1 receptor agonist (GLP-1RA) treatment can improve adipose distribution. We performed this meta-analysis to investigate whether GLP-1RAs preferentially reduce visceral adipose tissue (VAT) over subcutaneous adipose tissue (SAT) in patients with type 2 diabetes.
We searched MEDLINE and the Cochrane Library for randomised controlled trials explicitly reporting changes in VAT and SAT. A random-effects model was performed to estimate the weighted mean difference (MD) for VAT and SAT. Heterogeneity among the studies was assessed using I2 statistics, and publication bias was assessed using Egger's tests. Meta-regression was performed to identify the correlation between changes in adipose tissues and changes in body weight and glycated haemoglobin level.
Ten trials with 924 patients were enrolled in the meta-analysis. GLP-1RA treatment led to similar absolute area (cm2) reductions in VAT (MD -21.13 cm2, 95% CI [-29.82, -12.44]) and SAT (MD -22.89 cm2, 95% CI [-29.83, -15.95]). No significant publication bias was detected, and this result was stable in the sensitivity and subgroup analyses. Moreover, GLP-1RA treatment resulted in a greater reduction in VAT and SAT in the subgroup with a greater reduction in body weight. The absolute area reduction in VAT was significantly correlated with the reduction in body weight (r = 6.324, p = 0.035).
GLP-1RA treatment leads to significant and similar absolute reductions in VAT and SAT, and the reduction in adipose tissues may be correlated with the reduction in body weight.
胰高血糖素样肽 1 受体激动剂（GLP-1RA）治疗可改善脂肪分布。我们进行了这项荟萃分析，以研究 2 型糖尿病患者的 GLP-1RA 是否优先减少内脏脂肪组织（VAT）而不是皮下脂肪组织（SAT）。
我们检索了 MEDLINE 和 Cochrane 图书馆中明确报告 VAT 和 SAT 变化的随机对照试验。采用随机效应模型估计 VAT 和 SAT 的加权均数差值（MD）。使用 I2 统计量评估研究之间的异质性，并使用 Egger 检验评估发表偏倚。进行了 meta 回归以确定脂肪组织变化与体重和糖化血红蛋白水平变化之间的相关性。
共有 10 项试验纳入了 924 名患者进行荟萃分析。GLP-1RA 治疗导致 VAT（MD -21.13 cm2，95%CI [-29.82，-12.44]）和 SAT（MD -22.89 cm2，95%CI [-29.83，-15.95]）的绝对面积减少相似。未发现显著的发表偏倚，且敏感性和亚组分析结果稳定。此外，GLP-1RA 治疗在体重减轻较大的亚组中导致 VAT 和 SAT 更大的减少。VAT 的绝对面积减少与体重减轻呈显著相关（r = 6.324，p = 0.035）。
GLP-1RA 治疗可显著且相似地减少 VAT 和 SAT 的绝对面积，脂肪组织的减少可能与体重减轻相关。
